Skip to main navigation Skip to main content
info(at)avldigital.remove-this.de
Deutsch English
Narrow Search
Search narrowed by
Last searches

Results for *

Displaying results 1 to 3 of 3.

  1. Is medicine an ivory tower?
    induced innovation, technology opportunity, and for-profit vs. non-profit innovation
    Author: Bhattacharya, Jay; Packalen, Mikko
    Published: 2008
    Publisher:  National Bureau of Economic Research, Cambridge, Mass.

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (13862)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 13862
    Subjects: Gesundheitsrisiko; Medizin; Pharmakologie; Innovation; Endogenes Wachstumsmodell; USA
    Scope: 27, [28] S., graph. Darst.
  2. The other ex-ante moral hazard in health
    Author: Bhattacharya, Jay; Packalen, Mikko
    Published: 2008
    Publisher:  National Bureau of Economic Research, Cambridge, Mass.

    "It is well known that public or pooled insurance coverage can induce a form of ex-ante moral hazard: people make inefficiently low investments in self-protective activities. This paper points out another ex-ante moral hazard that arises through an... more

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Signature:
    W 1 (13863)
    Inter-library loan:
    Unlimited inter-library loan, copies and loan

     

    "It is well known that public or pooled insurance coverage can induce a form of ex-ante moral hazard: people make inefficiently low investments in self-protective activities. This paper points out another ex-ante moral hazard that arises through an induced innovation externality. This alternative mechanism, by contrast, causes people to devote an inefficiently high level of self-protection. As an empirical example of this externality, we analyze the innovation induced by the obesity epidemic. Obesity is associated with an increase in the incidence of many diseases. The induced innovation hypothesis is that an increase in the incidence of a disease will increase technological innovation specific to that disease. The empirical economics literature has produced substantial evidence in favor of the induced innovation hypothesis.We first estimate the associations between obesity and disease incidence. We then show that if these associations are causal and the pharmaceutical reward system is optimal the magnitude of the induced innovation externality of obesity roughly coincides with the Medicare-induced health insurance externality of obesity. The current Medicare subsidy for obesity therefore appears to be approximately optimal. We also show that the pattern of diseases for obese and normal weight individuals are similar enough that the induced innovation externality of obesity on normal weight individuals is positive as well"--National Bureau of Economic Research web site

     
    Export to reference management software   RIS file
      BibTeX file
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Print
    Series: NBER working paper series ; 13863
    Subjects: Gesundheitskosten; Gesundheitsrisiko; Pharmakologie; Innovation; Krankenversicherung; Moral Hazard; Externer Effekt; USA
    Scope: 26, [24] S., graph. Darst.
  3. The other ex-ante moral hazard in health
    Author: Bhattacharya, Jay; Packalen, Mikko
    Published: 2010
    Publisher:  Dep. of Economics, Univ. of Waterloo, Waterloo, Ontario

    Location:
    Universitätsbibliothek Braunschweig
    Inter-library loan:
    No inter-library loan

    Location:
    ZBW - Leibniz-Informationszentrum Wirtschaft, Standort Kiel
    Inter-library loan:
    No inter-library loan
    Export to reference management software   RIS file
      BibTeX file
    Content information
    Source: Union catalogues
    Language: English
    Media type: Book
    Format: Online
    Series: Waterloo economic series ; 10,015
    Subjects: Gesundheitskosten; Gesundheitsrisiko; Pharmakologie; Innovation; Krankenversicherung; Moral Hazard; Externer Effekt; USA
    Scope: Online-Ressource (40 S., 271,51 Kb), graph. Darst.